# Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW

> **NCT05359874** · PHASE2 · WITHDRAWN · sponsor: **Technical University of Munich**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumab-IRDye800CW

## Key facts

- **NCT ID:** NCT05359874
- **Lead sponsor:** Technical University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06
- **Primary completion:** 2023-03
- **Final completion:** 2023-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** application has been withdrawn
- **Last updated:** 2022-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359874, "Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05359874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*